Effectiveness and Safety of Teclistamab in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Results of the French Real-World RetrosTECtive Study

被引：0

作者：

Perrot, Aurore ^{[1
]}

Hulin, Cyrille ^{[2
]}

Harel, Stephanie ^{[3
]}

Manjrah, Hamza ^{[4
]}

Leveque, Antoine ^{[5
]}

Croizier, Carolyne ^{[6
]}

Dony, Arthur ^{[7
]}

Mohty, Mohamad ^{[8
,9
]}

Manier, Salomon ^{[10
]}

Roussel, Murielle ^{[11
]}

Orsini-Piocelle, Frederique ^{[12
]}

Bauschert, Loic ^{[13
]}

Coste, Arthur ^{[14
]}

Frenzel, Laurent ^{[15
]}

Vincent, Laure ^{[16
]}

Breal, Claire ^{[17
]}

Eveillard, Jean Richard ^{[18
]}

Gerome, Thomas ^{[19
]}

Tiab, Mourad ^{[20
]}

Chalayer, Emilie ^{[21
]}

Belkhir, Rakiba ^{[22
]}

Mariette, Clara ^{[23
]}

Moyer, Perrine ^{[24
]}

Boumendil, Ariane ^{[25
]}

Moreau, Philippe ^{[26
]}

机构：

[1] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[2] Univ Hosp, Hop Haut Leveque, Dept Hematol, Toulouse, France

[3] Hop St Louis, Assistance Publ Hop Paris, Serv Immunohematol, Paris, France

[4] Inst Paoli Calmettes, Marseille, France

[5] ICANS Strasbourg, Strasbourg, France

[6] CHU Clermont Ferrand, Clermont Ferrand, France

[7] Chambery Hosp, Imphal, Manipur, India

[8] Sorbonne Univ, Hop St Antoine, Paris, France

[9] INSERM, UMRS938, Paris, France

[10] Univ Lille, CHU Lille, Lille, France

[11] CHU Limoges, Limoges, France

[12] CH Annecy, Epagny Metz Tessy, France

[13] Lille St Vincent, Lille, France

[14] CHU Reims, Hop Robert Debre, Reims, France

[15] Hop Necker Enfants Malad, Paris, France

[16] Ctr Hosp Univ Montpellier, Dept Clin Hematol, Montpellier, France

[17] CH Lorient, Lorient, France

[18] CHU Brest, Brest, France

[19] CHU Caen, Caen, France

[20] CHD La Roche Sur Yon, La Roche Sur Yon, France

[21] CHU St Etienne, St Priest En Jarez, France

[22] Paris Bicetre, Le Kremlin Bicere, France

[23] CHU Grenoble, Grenoble, France

[24] CHU Nantes, Nantes, France

[25] IFM, Paris, France

[26] Univ Hosp Hotel Dieu, Hematol Dept, Paris, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-065

引用

页码：S78 / S79

页数：2

共 50 条

[1] Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad Z.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (06)
[2] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
Krishnan, Amrita Y.
Nooka, Ajay K.
Chari, Ajai
Garfall, Alfred L.
Martin, Thomas G.
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Eric, Ammann
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok V.
Slavcev, Mary
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Comparative effectiveness of teclistamab versus real-world physician's choice of therapy for patients with triple-class exposed relapsed/refractory multiple myeloma
Krishnan, Amrita
Nooka, Ajay
Chari, Ajai
Garfall, Alfred
Martin, Thomas
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Pei, Lixia
Ammann, Eric
Kobos, Rachel
Smit, Jennifer
Parekh, Trilok
Marshall, Alexander
Slavcev, Mary
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S174 - S174
[4] Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Philippe Moreau
María-Victoria Mateos
Maria Esther Gonzalez Garcia
Hermann Einsele
Valerio De Stefano
Lionel Karlin
Joanne Lindsey-Hill
Britta Besemer
Laure Vincent
Suriya Kirkpatrick
Michel Delforge
Aurore Perrot
Niels W. C. J. van de Donk
Charlotte Pawlyn
Salomon Manier
Xavier Leleu
Joaquin Martinez-Lopez
Francesca Ghilotti
Joris Diels
Raúl Morano
Claire Albrecht
Vadim Strulev
Imène Haddad
Lixia Pei
Rachel Kobos
Jennifer Smit
Mary Slavcev
Alexander Marshall
Katja Weisel
Advances in Therapy, 2024, 41 : 696 - 715
[5] Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison
Delforge, Michel
Anguille, Sebastien
Depaus, Julien
Meuleman, Nathalie
De Velde, Ann Van
Broek, Isabelle Vande
Diels, Joris
Erler-Yates, Nichola
Van Causenbroeck, Sebastien
Van Nimwegen, Kirsten
Vandervennet, Sophie
Lub, Susanne
Vekemans, Marie-Christiane Madeleine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S170 - S170
[6] Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios-Athanasios
Gavriatopoulou, Maria
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
[7] COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN'S CHOICE OF THERAPY (RWPC) FOR PATIENTS WITH TRIPLE-CLASS EXPOSED (TCE) RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Krishnan, A.
Nooka, A.
Chari, A.
Garfall, A. L.
Martin, T.
Nair, S.
Lin, X.
Qi, K.
Londhe, A.
Pei, L.
Ammann, E.
Chastain, K.
Parekh, T.
Marshall, A.
Slavcev, M.
Usmani, S. Z.
VALUE IN HEALTH, 2023, 26 (12) : S37 - S37
[8] Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma
Mateos, Maria-Victoria
van de Donk, Niels
Delforge, Michel
Einsele, Hermann
De Stefano, Valerio
Lindsey-Hill, Joanne
Vincent, Laure
Kirkpatrick, Suriya
Besemer, Britta
Gonzalez Garcia, Maria Esther
Karlin, Lionel
Ghilotti, Francesca
Diels, Joris
Morano, Raul
Albrecht, Claire
Strulev, Vadim
Haddad, Imene
Pei, Lixia
Kobos, Rachel
Smit, Jennifer
Slavcev, Mary
Marshall, Alexander
Weisel, Katja
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S199 - S199
[9] Comparative efficacy of teclistamab versus real-world physician's choice of therapy in the prospective LocoMMotion study in patients with triple-class exposed relapsed/refractory multiple myeloma
van de Donk, Niels W. C. J.
Moreau, Philippe
Delforge, Michel
Einsele, Hermann
Ghilotti, Francesca
Diels, Joris
Elsada, Ahmed
Strulev, Vadim
Pei, Lixia
Kobos, Rachel
Smit, Jennifer
Marshall, Alexander
Slavcev, Mary
Weisel, Katja
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S34
[10] Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Ye, Jing Christine
Biran, Noa
Nair, Sandhya
Lin, Xiwu
Qi, Keqin
Londhe, Anil
Ammann, Eric
Renaud, Thomas
Kane, Colleen
Parekh, Trilok
Gray, Kathleen
Peterson, Steve
Costa, Luciano J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02):

← 1 2 3 4 5 →